Drugs / ZT-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT05007977 | Jul 2021 → Apr 2022 | hypoglycemia, type 1 diabetes mellitus | Zucara Therapeutics Inc. | Terminated | Met primary Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT05762107 | Jul 2023 → Dec 2026 expected | type 1 diabetes mellitus | Zucara Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007977 ↗ |
| Action | Inhibit | “a novel somatostatin receptor 2 (SSTR2) antagonist” PMID 42168649 ↗ May 2026 |
| Route | Subcutaneous | “3 mg ZT-01 or 20 mg ZT-01 administered subcutaneously” PMID 42168649 ↗ May 2026 |
| Target | SSTR2 | “a novel somatostatin receptor 2 (SSTR2) antagonist” PMID 42168649 ↗ May 2026 |